This phase III randomized trial was designed to determine if granulocyte-macrophage colony-stimulating factor ( GM-CSF ) reduces the hematologic toxicity and morbidity induced by chemoradiotherapy in limited-stage small-cell lung cancer ( SCLC ) .
